{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T05:10:43Z","timestamp":1769749843785,"version":"3.49.0"},"reference-count":9,"publisher":"American Society of Hematology","issue":"10","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2003,5,15]]},"DOI":"10.1182\/blood-2003-02-0450","type":"journal-article","created":{"date-parts":[[2003,5,5]],"date-time":"2003-05-05T19:24:00Z","timestamp":1052162640000},"page":"4225-4225","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":14,"title":["Agranulocytosis unresponsive to growth factors following rituximab in vivo purging"],"prefix":"10.1182","volume":"101","author":[{"given":"Andrea L.","family":"Rose","sequence":"first","affiliation":[{"name":"1 Correspondence: Andrea L. Rose, Fred Hutchinson Cancer Research Center, Clinical, Seattle, WA; e-mail:arose@fhcrc.org"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice M.","family":"Forsythe","sequence":"additional","affiliation":[{"name":"1 Correspondence: Andrea L. Rose, Fred Hutchinson Cancer Research Center, Clinical, Seattle, WA; e-mail:arose@fhcrc.org"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David G.","family":"Maloney","sequence":"additional","affiliation":[{"name":"1 Correspondence: Andrea L. Rose, Fred Hutchinson Cancer Research Center, Clinical, Seattle, WA; e-mail:arose@fhcrc.org"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"key":"2020071613375887500_B1","first-page":"115","article-title":"Stem cell function and engraftment is not affected by \u201cin vivo purging\u201d with rituximab for autologous stem cell treatment for patients with low-grade non-Hodgkin's lymphoma.","volume":"26","author":"Buckstein","year":"1999","journal-title":"Semin Oncol."},{"key":"2020071613375887500_B2","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/S1083-8791(00)70028-0","article-title":"Immunotherapy with rituximab during peripheral blood stem cell transplantation for non-Hodgkin's lymphoma.","volume":"6","author":"Flinn","year":"2000","journal-title":"Biol Blood Marrow Transplant."},{"key":"2020071613375887500_B3","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/sj.bmt.1703515","article-title":"Rituximab in vivo purging is safe and effective in combination with CD34-positive selected autologous stem cell transplantation for salvage therapy in B-NHL.","volume":"29","author":"Flohr","year":"2002","journal-title":"Bone Marrow Transplant."},{"key":"2020071613375887500_B4","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1046\/j.1365-2141.2000.02084.x","article-title":"In vivo depletion of B cells using a combination of high-dose cytosine arabinoside\/mitoxantrone and rituximab for autografting in patients with non-Hodgkin's lymphoma.","volume":"109","author":"Voso","year":"2000","journal-title":"Br J Haematol."},{"key":"2020071613375887500_B5","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1046\/j.1365-2141.2002.03256.x","article-title":"A sequence of immuno-chemotherapy with Rituximab, mobilization of in vivo purged stem cells, high-dose chemotherapy and autotransplant is an effective and non-toxic treatment for advanced follicular and mantle cell lymphoma.","volume":"116","author":"Lazzarino","year":"2002","journal-title":"Br J Haematol."},{"key":"2020071613375887500_B6","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1182\/blood.V96.3.864","article-title":"Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion.","volume":"96","author":"Magni","year":"2000","journal-title":"Blood."},{"key":"2020071613375887500_B7","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1200\/JCO.2000.18.5.947","article-title":"Therapy-related myelodysplasia and secondary acute myelogenous leukemia after high-dose therapy with autologous hematopoietic progenitor-cell support for lymphoid malignancies.","volume":"18","author":"Micallef","year":"2000","journal-title":"J Clin Oncol."},{"key":"2020071613375887500_B8","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1007\/s002770100360","article-title":"Immunosuppressive therapy for patients with refractory anemia.","volume":"80","author":"Asano","year":"2001","journal-title":"Ann Hematol."},{"key":"2020071613375887500_B9","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1046\/j.1365-2141.1998.00551.x","article-title":"Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow.","volume":"100","author":"Jonasova","year":"1998","journal-title":"Br J Haematol."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/101\/10\/4225\/1261233\/h81003004222c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/101\/10\/4225\/1261233\/h81003004222c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T00:16:31Z","timestamp":1594944991000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/101\/10\/4225\/19344\/Agranulocytosis-unresponsive-to-growth-factors"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,5,15]]},"references-count":9,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2003,5,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2003-02-0450","relation":{},"ISSN":["1528-0020","0006-4971"],"issn-type":[{"value":"1528-0020","type":"electronic"},{"value":"0006-4971","type":"print"}],"subject":[],"published":{"date-parts":[[2003,5,15]]}}}